Insider · CIK 0001422772

Kim Helen Susan

Reports to the SEC for 9 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001422772

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-12	AKTSAktis Oncology, Inc.C Conversion	Director, 10% Owner	CConversion	+4.86M sh	—	—	4,859,370
2026-01-12	AKTSAktis Oncology, Inc. · Series A Redeemable Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−14.8M sh	—	—	0
2026-01-12	AKTSAktis Oncology, Inc. · Series A Redeemable Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−412K sh	—	—	0
2026-01-12	AKTSAktis Oncology, Inc.C Conversion	Director, 10% Owner	CConversion	+135K sh	—	—	134,842
2026-01-12	AKTSAktis Oncology, Inc. · Series B Redeemable Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−101K sh	—	—	0
2026-01-12	AKTSAktis Oncology, Inc.P Purchase	Director, 10% Owner	PPurchase	+812K sh	$18.00	+$14.6M	5,671,825
2026-01-12	AKTSAktis Oncology, Inc.P Purchase	Director, 10% Owner	PPurchase	+22.5K sh	$18.00	+$406K	157,387
2026-01-12	AKTSAktis Oncology, Inc. · Series B Redeemable Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−3.65M sh	—	—	0
2025-05-14	PRTAPROTHENA CORP PUBLIC LTD CO · Stock Option (Right to Buy)A Award	Director	AAward	+20.2K sh	—	—	20,183
2024-05-15	PRTAPROTHENA CORP PUBLIC LTD CO · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2023-05-17	PRTAPROTHENA CORP PUBLIC LTD CO · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2022-08-31	PRTAPROTHENA CORP PUBLIC LTD CO · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2021-08-27	Applied Molecular Transport Inc.S Sale	Director	SSale	−250 sh	$31.44	−$7,860.5	575,000
2021-08-27	Applied Molecular Transport Inc.S Sale	Director	SSale	−701 sh	$30.76	−$21.6K	575,250
2021-08-26	Applied Molecular Transport Inc.S Sale	Director	SSale	−558 sh	$31.01	−$17.3K	575,951
2021-08-26	Applied Molecular Transport Inc.S Sale	Director	SSale	−13.5K sh	$30.12	−$407K	576,509
2021-08-25	Applied Molecular Transport Inc.S Sale	Director	SSale	−9,478 sh	$30.08	−$285K	590,014
2021-08-24	Applied Molecular Transport Inc.S Sale	Director	SSale	−3 sh	$30.04	−$90.12	599,492
2021-08-24	Applied Molecular Transport Inc.S Sale	Director	SSale	−505 sh	$30.03	−$15.2K	599,495
2021-07-02	Applied Molecular Transport Inc.S Sale	Director	SSale	−1,241 sh	$46.31	−$57.5K	600,000
2021-07-02	Applied Molecular Transport Inc.S Sale	Director	SSale	−199K sh	$43.30	−$8.61M	601,241
2021-05-18	Applied Molecular Transport Inc.Stock Option (Right to Buy)A Award	Director	AAward	+14.3K sh	—	—	14,343
2020-07-02	Applied Molecular Transport Inc.M Exercise/Conversion	Director	MExercise/Conversion	+800K sh	$0.02	+$16K	800,000
2020-07-02	Applied Molecular Transport Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−800K sh	—	—	0
2020-06-11	ASMBASSEMBLY BIOSCIENCES, INC. · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2020-06-04	XCUREXICURE, INC. · Stock Option (right to buy)A Award	Director	AAward	+21.7K sh	—	—	21,693
2019-06-14	XCUREXICURE, INC. · Stock Option (right to buy)A Award	Director	AAward	+21.7K sh	—	—	21,693
2019-05-17	ASMBASSEMBLY BIOSCIENCES, INC. · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2018-06-19	XCUREXICURE, INC. · Stock Option (right to buy)A Award	Director	AAward	+21.7K sh	—	—	21,693
2018-05-30	ASMBASSEMBLY BIOSCIENCES, INC. · Stock Option (right to buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2018-03-08	ASMBASSEMBLY BIOSCIENCES, INC. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−18.6K sh	—	—	0
2017-10-03	Kite Pharma, Inc.U Disposition from Tender	EVP, Business Development	UDisposition from Tender	−4,193 sh	$180.00	−$755K	17,500
2017-10-03	Kite Pharma, Inc.D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−17.5K sh	—	—	0
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−14.4K sh	$116.13	−$1.68M	0
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−38.5K sh	—	—	0
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−52.5K sh	—	—	0
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−2,499 sh	$128.57	−$321K	0
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−3,752 sh	$126.10	−$473K	0
2017-10-03	Kite Pharma, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	EVP, Business Development	DDisposition to Issuer	−35K sh	—	—	0
2017-09-26	XCUREXICURE, INC. · Stock Option (right to buy)A Award	Director	AAward	+24.8K sh	—	—	24,824
2017-09-26	XCUREXICURE, INC. · Stock Option (right to buy)A Award	Director	AAward	+24.8K sh	—	—	24,824
2017-09-26	XCUREXICURE, INC. · Stock Option (right to buy)A Award	Director	AAward	+49.6K sh	—	—	49,649
2017-09-25	Kite Pharma, Inc.S Sale	EVP, Business Development	SSale	−3,171 sh	$179.66	−$570K	21,693
2017-09-25	Kite Pharma, Inc.A Award	EVP, Business Development	AAward	+6,000 sh	—	—	24,864
2017-08-10	Kite Pharma, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	EVP, Business Development	MExercise/Conversion	−2,656 sh	—	—	37,344
2017-08-10	Kite Pharma, Inc.M Exercise/Conversion	EVP, Business Development	MExercise/Conversion	+2,656 sh	$51.43	+$137K	24,915
2017-08-10	Kite Pharma, Inc.S Sale	EVP, Business Development	SSale	−6,251 sh	$120.09	−$751K	18,664
2017-08-10	Kite Pharma, Inc.M Exercise/Conversion	EVP, Business Development	MExercise/Conversion	+3,595 sh	$53.90	+$194K	22,259
2017-08-10	Kite Pharma, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	EVP, Business Development	MExercise/Conversion	−3,595 sh	—	—	56,407

Recent filings

Accepted (ET)
Jan 124
Kim Helen Susan0001193125-26-010566
SEC(opens sec.gov)
May 164
Kim Helen Susan0000905148-25-001832
SEC(opens sec.gov)
May 174
Kim Helen Susan0000905148-24-001538
SEC(opens sec.gov)
May 194
Kim Helen Susan0001140361-23-025826
SEC(opens sec.gov)
Sep 24
Kim Helen Susan0001567619-22-017016
SEC(opens sec.gov)
Aug 274
Kim Helen Susan0001209191-21-053763
SEC(opens sec.gov)
Aug 254
Kim Helen Susan0001209191-21-053411
SEC(opens sec.gov)
Jul 64
Kim Helen Susan0001209191-21-045674
SEC(opens sec.gov)

Companies

Address

C/O AKTIS ONCOLOGY, INC. 17 DRYDOCK AVENUE, SUITE 17-401

BOSTON, MA, 02210